NTLA News and Press, Intellia Therapeutics Inc. From 02/12/26

2026-02-12 22:37:04 ET This article is part of a series that provides an ongoing analysis of the changes made to ARK Invest’ 13F portfolio on a quarterly basis. It is based on their regulatory 13F Form filed on 02/11/2026.... Read the full article on Seeking Alpha ...

2026-02-07 09:25:00 ET Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could revolutionize medicine by helping researchers develop therapies for disea...

2026-02-05 13:55:23 ET Investment Overview - Understanding Gene Therapies Risk/Reward In my last note on Intellia Therapeutics ( NTLA ) for Seeking Alpha, at the beginning of December last year, I downgraded my rating on the gene therapy specialist's stock to Hold.... ...

2026-01-28 08:05:23 ET Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine DENVER, Colo – CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine ...

2026-01-28 06:15:16 ET H.C. Wainwright analyst issues BUY recommendation for NTLA on January 28, 2026 11:08AM ET. The previous analyst recommendation was Buy. NTLA was trading at $14.83 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curr...

2026-01-27 15:15:03 ET Citigroup analyst issues OUTPERFORM recommendation for NTLA on January 27, 2026 08:02PM ET. The previous analyst recommendation was Outperform. NTLA was trading at $14.83 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2026-01-27 13:19:42 ET Jack Allen from Robert W. Baird issued a price target of $7.00 for NTLA on 2026-01-27 16:29:00. The adjusted price target was set to $7.00. At the time of the announcement, NTLA was trading at $14.395. The overall price target consensus is at $18.5...

2026-01-27 09:41:47 ET Denver, Colorado- This morning’s news flow highlights how innovation is translating into execution across robotics, industrial automation, defense, and life sciences. Richtech Robotics (NASDAQ:RR) set the tone with news of a hands-on engineering...

2026-01-27 08:31:34 ET More on Intellia Therapeutics, Regeneron Pharmaceuticals Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026 Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate Intellia Therapeutics, Inc. (NTLA) Pr...

Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing compa...